Icon (NASDAQ:ICLR) Director Ciaran Murray Sells 2,677 Shares of Stock

Icon Plc (NASDAQ:ICLR) Director Ciaran Murray sold 2,677 shares of Icon stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $439,804.33. Following the completion of the transaction, the director directly owned 20,452 shares in the company, valued at $3,360,059.08. This trade represents a 11.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Up 1.0%

Shares of ICLR opened at $167.17 on Thursday. The firm has a 50 day simple moving average of $161.93 and a two-hundred day simple moving average of $134.18. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. Icon Plc has a one year low of $66.57 and a one year high of $203.91. The company has a market cap of $12.80 billion, a P/E ratio of 39.24, a P/E/G ratio of 6.86 and a beta of 1.21.

Icon (NASDAQ:ICLR) last issued its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. During the same quarter last year, the business posted $3.26 EPS. The company’s revenue was up 2.3% compared to the same quarter last year. Research analysts forecast that Icon Plc will post 9.57 EPS for the current fiscal year.

Icon News Roundup

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted earnings were $2.56 per share versus a $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue grew 2.3% year over year, supporting the stock despite lower earnings than the prior-year quarter.
• Positive Sentiment: Several analysts maintain bullish targets above recent trading levels. BMO Capital Markets raised its target to $187 and Mizuho lifted its target to $190, while the broader analyst consensus is a “Hold” with an average target of $170.40. Should You Bring The Luck Of The Irish To Your Investments?
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth approximately $62,675, while CFO Nigel Clerkin sold 2,267 shares worth about $372,445. Six directors also sold shares, including Ciaran Murray’s approximately $439,804 transaction. All sales were disclosed as tax-withholding transactions tied to equity award vesting, and the executives and directors retained stock afterward. Icon CEO Sells Stock
• Neutral Sentiment: Reported short interest was zero shares, indicating no measurable short-selling pressure; however, this also provides limited evidence of potential short-covering support.
• Neutral Sentiment: ICLR trades well above its 200-day moving average and carries a relatively elevated valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88. This suggests investors are already pricing in substantial future growth.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ICLR. EFG International AG bought a new stake in Icon during the 4th quarter worth approximately $27,000. Abound Financial LLC acquired a new position in Icon in the 4th quarter valued at approximately $54,000. GAMMA Investing LLC raised its stake in shares of Icon by 21.4% during the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 69 shares during the last quarter. Johnson Financial Group Inc. bought a new position in shares of Icon during the third quarter valued at $71,000. Finally, Blue Trust Inc. lifted its holdings in shares of Icon by 207.5% during the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on ICLR shares. TD Cowen boosted their target price on Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Weiss Ratings cut shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Bank of America raised their target price on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research report on Thursday, June 25th. Mizuho boosted their target price on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. Finally, DA Davidson set a $164.00 price target on shares of Icon in a report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.